
Balaxi Pharmaceuticals (BALAXI) Share Price Falls 8.2% in Latest Session
Updated: 20 Nov 2026 • 9:56 am
Posted by:

Balaxi Pharmaceuticals Share Price is trading at Rs 34.24 after a fall of 8.2% from the previous close, with market capitalisation at Rs 174.73 crore. The move keeps Balaxi Pharmaceuticals Share Price in focus for investors tracking Balaxi Pharmaceuticals Share Price Today, Balaxi Pharmaceuticals Stock News and Balaxi Pharmaceuticals Share Price Fall on Univest. Univest figures confirm the price action, but they do not point to a specific company trigger. The stock opened at Rs 36.49, touched a high of Rs 36.49 and a low of Rs 33.60, so the latest Balaxi Pharmaceuticals Share Price move is best read as a sharp intraday decline rather than a broad multi-day trend. For readers following Balaxi Pharmaceuticals Share Price News, the first question is whether the price action is supported by fundamentals; the next sections address that with valuation, returns and peer context.
Balaxi Pharmaceuticals (BALAXI) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 34.24 |
| Previous Close | Rs 37.3 |
| Today's Move | -Rs 3.06 (-8.2%) |
| Open | Rs 36.49 |
| High | Rs 36.49 |
| Low | Rs 33.6 |
| Market Capitalisation | Rs 174.73 crore |
| Market Cap Category | Micro Cap |
Balaxi Pharmaceuticals Share Price is trading at Rs 34.24, which is Rs 3.06 below the previous close of Rs 37.30. The day change is -8.2%, and the stock moved between an intraday high of Rs 36.49 and a low of Rs 33.60. Balaxi Pharmaceuticals Share Price Today therefore shows a gap between the opening level and the final observed trading level, while the day range also places the stock close to the lower end of the band. The company belongs to the Micro Cap category, with market capitalisation of Rs 174.73 crore. For Balaxi Pharmaceuticals Share Price watchers, the key fact is simple: the stock has lost ground in the latest session and the move is large enough to matter in Balaxi Pharmaceuticals Share Price News and Balaxi Pharmaceuticals Stock Analysis. The next check is whether the fundamentals justify the current Balaxi Pharmaceuticals Share Price valuation.
Balaxi Pharmaceuticals (BALAXI) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 174.73 crore |
| P/E Ratio | 61.2x |
| P/B Ratio | 0.81x |
| ROE | 0.59% |
| ROCE | 3.48% |
| EPS | Rs 0.61 |
| Book Value Per Share | Rs 46.04 |
| Dividend Yield | 0% |
Balaxi Pharmaceuticals (BALAXI) fundamental metrics show P/E 61.2x, P/B 0.81x, ROE 0.59%, ROCE 3.48%. Taken on their own, these numbers offer context rather than a trading signal.
Balaxi Pharmaceuticals has a market capitalisation of Rs 174.73 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 61.2x, P/B at 0.81x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 0.59% and ROCE of 3.48%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 0.61, book value per share of Rs 46.04, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 22.46x, median ROE of 4.11%, median ROCE of 6.06%. They set out the fundamental picture and are not a rating on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Trading |
| Industry | Trading |
| Benchmark Scope | same industry |
| Company P/E Ratio | 61.2x |
| Benchmark Median P/E | 22.46x |
| Benchmark Average P/E | 91.1x |
| Benchmark P/E Range | 0.1x to 4,869.11x |
| Company P/B Ratio | 0.81x |
| Benchmark Median P/B | 1.33x |
| Benchmark Average P/B | 1.27x |
| Company ROE | 0.59% |
| Benchmark Median ROE | 4.11% |
| Benchmark Average ROE | 4.24% |
| Company ROCE | 3.48% |
| Benchmark Median ROCE | 6.06% |
| Benchmark Average ROCE | 3.7% |
| Company Market Capitalisation | Rs 174.73 crore |
| Benchmark Median Market Cap | Rs 53.16 crore |
| Benchmark Average Market Cap | Rs 1,506.91 crore |
Balaxi Pharmaceuticals (BALAXI) operates in the Trading sector, within the Trading industry.
Balaxi Pharmaceuticals (BALAXI) has a P/E ratio of 61.2x, which is above the benchmark median of 22.46x, a difference of +172.48%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Balaxi Pharmaceuticals (BALAXI) has a ROE of 0.59%, which is below the benchmark median of 4.11%, a difference of -85.64%. Balaxi Pharmaceuticals (BALAXI) has a ROCE of 3.48%, which is below the benchmark median of 6.06%, a difference of -42.57%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Adani Enterprises | ADANIENT | 3,63,704.65 | 63.65 | 3.73 | 15.07 | 13.3 |
| ADITYA INFOTECH | CPPLUS | 48,347.46 | 83.28 | 13.45 | 25.68 | 29.48 |
| Aegis Logistics | AEGISLOG | 44,745.74 | 33.33 | 4.37 | 20.71 | 19.76 |
| Premier Energies | PREMIERENE | 37,904.95 | 21.32 | 7.3 | 42.6 | 33.72 |
| Redington | REDINGTON | 26,427.88 | 14.39 | 2.48 | 13.6 | 18.96 |
Balaxi Pharmaceuticals (BALAXI) has a P/E ratio of 61.2x compared with the displayed peer median of 33.33x. The comparison is relative and should not be read as a recommendation. Its ROE of 0.59% compares with a peer median of 20.71% across the companies shown in the table. ROCE stood at 3.48% versus the displayed peer median of 19.76%, providing a capital-efficiency comparison. Balaxi Pharmaceuticals (BALAXI) has a market capitalisation of Rs 174.73 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Balaxi Pharmaceuticals
- Balaxi Pharmaceuticals Share Price is down 8.2% in the latest session, and the move is large enough to stand out in Balaxi Pharmaceuticals Share Price Today coverage.
- The stock is trading at Rs 34.24 after opening at Rs 36.49 and touching Rs 33.60, so Balaxi Pharmaceuticals Share Price remains active within a defined intraday band.
- Balaxi Pharmaceuticals Share Price carries a P/E of 61.2 and a P/B of 0.81, giving investors a mixed valuation picture to assess.
- ROE of 0.59% and ROCE of 3.48% keep the focus on return efficiency in Balaxi Pharmaceuticals Fundamental Analysis.
- Balaxi Pharmaceuticals Share Price sits in the Micro Cap category, and the company’s market capitalisation is Rs 174.73 crore.
About Balaxi Pharmaceuticals
Balaxi Pharmaceuticals operates in the Trading sector and Trading industry. The latest company context available to Univest readers places Balaxi Pharmaceuticals Share Price within a business model framed by trading activity rather than a diversified operating profile. For Balaxi Pharmaceuticals Share Price News, that matters because traders and investors often read the stock through valuation, return ratios and market-cap placement rather than through large-scale operating disclosures. Balaxi Pharmaceuticals Share Price therefore sits in a niche where market capitalisation, P/E, P/B, ROE, ROCE, EPS and book value are the main reference points in this article. The company’s latest share-price move is the event in focus, while its sector placement provides the broader context for Balaxi Pharmaceuticals Share Price Today.
Track Balaxi Pharmaceuticals Share Price on Univest
Use Balaxi Pharmaceuticals (BALAXI) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Univest helps readers track Balaxi Pharmaceuticals Share Price with live price updates, fundamental ratios, 52-week levels and market insights in one place. If you are following Balaxi Pharmaceuticals Share Price Today, you can use Univest to review price action, valuation context and company overview without switching between multiple sources. Balaxi Pharmaceuticals Share Price remains relevant for investors who monitor stock movements, sector context and company-specific financial ratios on a single platform.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
What is Balaxi Pharmaceuticals Share Price today?
Ans. Balaxi Pharmaceuticals Share Price is trading at Rs 34.24. The stock is down 8.2% from the previous close of Rs 37.30, which keeps Balaxi Pharmaceuticals Share Price Today in focus for readers tracking the latest move.
Why did Balaxi Pharmaceuticals Share Price fall today?
Ans. Univest figures confirm the price action, but they do not point to a specific company trigger. Balaxi Pharmaceuticals Share Price fell 8.2% in the latest session, and the visible figures show only the move, not a verified trigger.
What was the previous close for Balaxi Pharmaceuticals Share Price?
Ans. The previous close for Balaxi Pharmaceuticals Share Price was Rs 37.30. The stock then moved to Rs 34.24, creating a day change of Rs 3.06 lower and a percentage decline of 8.2%.
What is the market capitalisation of Balaxi Pharmaceuticals?
Ans. Balaxi Pharmaceuticals has a market capitalisation of Rs 174.73 crore. That places Balaxi Pharmaceuticals Share Price in the Micro Cap category and well below the average market cap in the same-industry benchmark.
How is Balaxi Pharmaceuticals Share Price valued?
Ans. Balaxi Pharmaceuticals Share Price trades at a P/E of 61.2 and a P/B of 0.81. The earnings multiple is above the benchmark median, while the book-value multiple is below the benchmark median, creating a mixed valuation setup.
What do ROE and ROCE show for Balaxi Pharmaceuticals?
Ans. Balaxi Pharmaceuticals reports ROE of 0.59% and ROCE of 3.48%. Both ratios are below the benchmark medians for the Trading industry, so Balaxi Pharmaceuticals Share Price is not backed by strong return ratios in the current figures.
Does Balaxi Pharmaceuticals pay a dividend?
Ans. The dividend yield is 0% for Balaxi Pharmaceuticals. That means Balaxi Pharmaceuticals Share Price does not currently have a dividend yield figure supporting the stock, so investors are reading it mainly through valuation and return metrics.
How does Balaxi Pharmaceuticals compare with Trading peers?
Ans. Balaxi Pharmaceuticals Share Price has a much smaller market cap than the selected peers, and its ROE and ROCE are lower than all five comparison names. Its P/E is below some peers and above others, so the comparison is mixed.
Should investors track Balaxi Pharmaceuticals Share Price on Univest?
Ans. Yes, investors tracking Balaxi Pharmaceuticals Share Price can use Univest for live price updates, valuation ratios and market context. The stock’s latest decline, micro-cap size and peer comparison make it a useful name to monitor closely.
Recent Articles

Gujarat Fluorochemicals (FLUOROCHEM) 52 Week High Streak: Back-to-Back Highs Keep Focus on the Stock
20 November 2026

TVS Motor Company Ltd. (TVSMOTOR) 52 Week High Streak: TVSMOTOR trades near one-year peak for second straight session
20 November 2026

SWASTIKA INFRA (SWASTIKAIN) 52 Week Low Streak: Second Straight Session Near One-Year Low
20 November 2026

DCB Bank Ltd. (DCBBANK) 52 Week High Streak: What The Pattern Shows
20 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Gujarat Fluorochemicals (FLUOROCHEM) 52 Week High Streak: Back-to-Back Highs Keep Focus on the Stock
TVS Motor Company Ltd. (TVSMOTOR) 52 Week High Streak: TVSMOTOR trades near one-year peak for second straight session
SWASTIKA INFRA (SWASTIKAIN) 52 Week Low Streak: Second Straight Session Near One-Year Low
DCB Bank Ltd. (DCBBANK) 52 Week High Streak: What The Pattern Shows
Mena Mani Industries Ltd. Hits Lower Circuit for the 2nd Straight Session on BSE, 20 November 2026

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





